title: Coexistent BCR-ABL1 and JAK2 V617F:  converting CML dwarves to ET staghorns with  imatinib therapy.
authors.forename: Craig
authors.initials: C
authors.lastname: Soderquist
authors.forename: Adam
authors.initials: A
authors.lastname: Bagg
mesh_terms: D000368:Aged; D019943:Amino Acid Substitution; D001549:Benzamides / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008533:Megakaryocytes / Q000473:pathology*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: C581634:BCR-ABL1 fusion protein, human; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C507924:JAK2 protein, human; D053614:Janus Kinase 2